mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19

Increased pneumocyte expression of the SARS-CoV-2 entry receptor ACE2 in lymphangioleiomyomatosis (LAM) is associated with upregulation of interferon pathways in natural killer cells as well as increased IL6 expression in LAM-associated fibroblasts https://bit.ly/34ChSsg

Detalles Bibliográficos
Autores principales: Tang, Yan, Kwiatkowski, David J., Henske, Elizabeth P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7562695/
https://www.ncbi.nlm.nih.gov/pubmed/33060154
http://dx.doi.org/10.1183/13993003.02737-2020
_version_ 1783595327107891200
author Tang, Yan
Kwiatkowski, David J.
Henske, Elizabeth P.
author_facet Tang, Yan
Kwiatkowski, David J.
Henske, Elizabeth P.
author_sort Tang, Yan
collection PubMed
description Increased pneumocyte expression of the SARS-CoV-2 entry receptor ACE2 in lymphangioleiomyomatosis (LAM) is associated with upregulation of interferon pathways in natural killer cells as well as increased IL6 expression in LAM-associated fibroblasts https://bit.ly/34ChSsg
format Online
Article
Text
id pubmed-7562695
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-75626952020-10-20 mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19 Tang, Yan Kwiatkowski, David J. Henske, Elizabeth P. Eur Respir J Agora Increased pneumocyte expression of the SARS-CoV-2 entry receptor ACE2 in lymphangioleiomyomatosis (LAM) is associated with upregulation of interferon pathways in natural killer cells as well as increased IL6 expression in LAM-associated fibroblasts https://bit.ly/34ChSsg European Respiratory Society 2021-02-11 /pmc/articles/PMC7562695/ /pubmed/33060154 http://dx.doi.org/10.1183/13993003.02737-2020 Text en Copyright ©ERS 2021 http://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Agora
Tang, Yan
Kwiatkowski, David J.
Henske, Elizabeth P.
mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
title mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
title_full mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
title_fullStr mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
title_full_unstemmed mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
title_short mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
title_sort mtorc1 hyperactivation in lymphangioleiomyomatosis leads to ace2 upregulation in type ii pneumocytes: implications for covid-19
topic Agora
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7562695/
https://www.ncbi.nlm.nih.gov/pubmed/33060154
http://dx.doi.org/10.1183/13993003.02737-2020
work_keys_str_mv AT tangyan mtorc1hyperactivationinlymphangioleiomyomatosisleadstoace2upregulationintypeiipneumocytesimplicationsforcovid19
AT kwiatkowskidavidj mtorc1hyperactivationinlymphangioleiomyomatosisleadstoace2upregulationintypeiipneumocytesimplicationsforcovid19
AT henskeelizabethp mtorc1hyperactivationinlymphangioleiomyomatosisleadstoace2upregulationintypeiipneumocytesimplicationsforcovid19

Ejemplares similares